[go: up one dir, main page]

NO995853L - Nytt salt - Google Patents

Nytt salt

Info

Publication number
NO995853L
NO995853L NO995853A NO995853A NO995853L NO 995853 L NO995853 L NO 995853L NO 995853 A NO995853 A NO 995853A NO 995853 A NO995853 A NO 995853A NO 995853 L NO995853 L NO 995853L
Authority
NO
Norway
Prior art keywords
fresh salt
fresh
salt
Prior art date
Application number
NO995853A
Other languages
English (en)
Norwegian (no)
Other versions
NO995853D0 (no
Inventor
Hokan Nyqvist
Daniel D Sohn
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO995853D0 publication Critical patent/NO995853D0/no
Publication of NO995853L publication Critical patent/NO995853L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
NO995853A 1997-05-30 1999-11-29 Nytt salt NO995853L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702066A SE510305C2 (sv) 1997-05-30 1997-05-30 Nytt salt
PCT/SE1998/000907 WO1998054166A1 (en) 1997-05-30 1998-05-15 A new salt

Publications (2)

Publication Number Publication Date
NO995853D0 NO995853D0 (no) 1999-11-29
NO995853L true NO995853L (no) 2000-01-31

Family

ID=20407187

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995853A NO995853L (no) 1997-05-30 1999-11-29 Nytt salt

Country Status (33)

Country Link
US (2) US6858645B2 (et)
EP (1) EP0984952B1 (et)
JP (1) JP3554338B2 (et)
KR (1) KR20010013127A (et)
CN (1) CN1198814C (et)
AR (1) AR012751A1 (et)
AT (1) ATE228121T1 (et)
AU (1) AU729301B2 (et)
BG (1) BG64051B1 (et)
BR (1) BR9809519A (et)
CA (1) CA2291732C (et)
DE (1) DE69809547T2 (et)
DK (1) DK0984952T3 (et)
EE (1) EE03874B1 (et)
ES (1) ES2187030T3 (et)
HU (1) HUP0001878A3 (et)
ID (1) ID23794A (et)
IL (1) IL133234A (et)
IS (1) IS1943B (et)
MY (1) MY117960A (et)
NO (1) NO995853L (et)
NZ (1) NZ501075A (et)
PL (1) PL337181A1 (et)
PT (1) PT984952E (et)
RU (1) RU2193560C2 (et)
SE (1) SE510305C2 (et)
SK (1) SK282755B6 (et)
TR (1) TR199902926T2 (et)
TW (1) TW510899B (et)
UA (1) UA53720C2 (et)
WO (1) WO1998054166A1 (et)
YU (1) YU62499A (et)
ZA (1) ZA984486B (et)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
AU2003256430A1 (en) * 2002-08-15 2004-03-03 Wyeth AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
EP2022110B1 (en) * 2006-05-11 2011-10-12 Johnson Controls Saft Advanced Power Solutions LLC Modular battery system
JP5163931B2 (ja) * 2007-03-08 2013-03-13 株式会社リコー 定着装置及び画像形成装置
EP2065385A1 (en) * 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
CN103788043B (zh) * 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶iv型、其制法和其药物组合物与用途
TWI615390B (zh) * 2013-04-26 2018-02-21 賽諾菲公司 ５－氯－噻吩－２－羧酸［（ｓ）－２－［甲基－３－（２－側氧基－吡咯啶－１－基）－苯磺醯基胺基］－３－（４－甲基－哌嗪－１－基）－３－側氧基－丙基］－醯胺之酒石酸鹽

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63474B1 (en) * 1987-12-24 1995-04-19 Wyeth John & Brother Ltd Heterocyclic compounds
US5616610A (en) 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
RU2047614C1 (ru) * 1992-06-15 1995-11-10 Джон Вайс энд Бразер Лимитед Гетероциклические соединения, или их фармацевтически приемлемые аддитивные соли кислоты, или n-оксид гетероциклического соединения, или его аддитивная соль кислоты
IT1282705B1 (it) 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria
US5990114A (en) 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence

Also Published As

Publication number Publication date
BG64051B1 (bg) 2003-11-28
IS5270A (is) 1999-11-24
BG103949A (en) 2000-07-31
SE9702066D0 (sv) 1997-05-30
DK0984952T3 (da) 2003-02-24
NZ501075A (en) 2001-08-31
IL133234A (en) 2004-05-12
JP2002501527A (ja) 2002-01-15
WO1998054166A1 (en) 1998-12-03
EP0984952A1 (en) 2000-03-15
SE510305C2 (sv) 1999-05-10
ID23794A (id) 2000-05-11
EP0984952B1 (en) 2002-11-20
YU62499A (sh) 2002-06-19
DE69809547T2 (de) 2003-08-21
BR9809519A (pt) 2000-06-20
EE03874B1 (et) 2002-10-15
TR199902926T2 (xx) 2000-03-21
SE9702066L (sv) 1998-12-01
HK1025575A1 (en) 2000-11-17
DE69809547D1 (de) 2003-01-02
US20050085532A1 (en) 2005-04-21
JP3554338B2 (ja) 2004-08-18
CN1198814C (zh) 2005-04-27
IL133234A0 (en) 2001-03-19
IS1943B (is) 2004-08-13
RU2193560C2 (ru) 2002-11-27
EE9900549A (et) 2000-06-15
NO995853D0 (no) 1999-11-29
PT984952E (pt) 2003-03-31
SK282755B6 (sk) 2002-12-03
AR012751A1 (es) 2000-11-08
SK159499A3 (en) 2000-10-09
MY117960A (en) 2004-08-30
AU7792398A (en) 1998-12-30
US6858645B2 (en) 2005-02-22
TW510899B (en) 2002-11-21
CA2291732C (en) 2003-12-30
HUP0001878A3 (en) 2002-04-29
ATE228121T1 (de) 2002-12-15
AU729301B2 (en) 2001-02-01
KR20010013127A (ko) 2001-02-26
ES2187030T3 (es) 2003-05-16
CN1258290A (zh) 2000-06-28
UA53720C2 (uk) 2003-02-17
US20030109576A1 (en) 2003-06-12
PL337181A1 (en) 2000-08-14
CA2291732A1 (en) 1998-12-03
ZA984486B (en) 1998-11-30
HUP0001878A2 (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
ID24829A (id) Garam natrium omeprazola
EP0913086A4 (en) BAIT
ID16866A (id) Kompleks kompleks inklusi garam-garam aril-heterosiklik
FI972566A7 (fi) Kalatiejärjestelmä
ID22849A (id) Penghambat-penghambat sulmafida-metaloprotease
EE9900448A (et) Ühendid
NO995853L (no) Nytt salt
ID18027A (id) Garam amina
FI963262A7 (fi) Ongenkoukku
ATE241275T1 (de) Phosphoniumsalz-zusammensetzung
EE9900602A (et) Ühendid
EE9900466A (et) Ühendid
DK0827503T3 (da) Pyrrolidinylmethylindol-salt
DE69805466D1 (de) Kastanienpfanne
BR9601758A (pt) Saleiro anti-umectante
DE69737634D1 (de) Insektizide oxadiazinverbindungen
KR970056464U (ko) 개량 낚시
KR970050593U (ko) 수족관
KR980000139U (ko) 낚시줄인양기
KR970000236U (ko) 수족관
BR7601850U (pt) Saleiro
NO970776D0 (no) Fiskeredskap
FI3149U1 (fi) Uistin
KR960005231U (ko) 염전용 개량물꼬
ATA131497A (de) Aquarium

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application